Efficacy and safety of first-line chemotherapy combined with immune checkpoint inhibitors for extensive-stage small cell lung cancer patients: a real-world propensity score matching study
our findings indicate that incorporating ICIs into first-line chemotherapy significantly improves PFS and OS in ES-SCLC patients, while maintaining safety. Moreover, poor ECOG PS, brain metastases, and high SIRI at baseline may serve as valuable prognostic indicators for disease progression and survival in ES-SCLC patients undergoing first-line chemotherapy plus ICIs. It is worth noting that these findings should be interpreted as hypothesis-generating, not definitive clinical conclusions.
Authors
- Bin Jia
- Shuaiyin Chen (ORCID: https://orcid.org/0000-0001-6129-0310)
- Huina Wang
- Quanman Hu (ORCID: https://orcid.org/0000-0003-4250-9713)
- Boying Wu
- Fei Zhao (ORCID: https://orcid.org/0009-0008-6335-4777)
- Chenyi Zhou (ORCID: https://orcid.org/0009-0008-5359-8196)
- X. Wang
- Yuan Ding (ORCID: https://orcid.org/0009-0009-4956-0889)
- Xiaoru Song
Institutions
- Zhengzhou University (CN)
- Zhengzhou University of Science and Technology (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-13
- DOI
- https://doi.org/10.3389/fimmu.2025.1562458
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Wu Jieping Medical Foundation